摘要目的分析健康教育配合利拉鲁肽单药治疗新诊断超重2型糖尿病的治疗效果，为临床应用提供理论依据及参考。方法选取2014年6月～2016年5月我院收治的30例超重2型糖尿病患者为研究对象，采用随机数字表法分为健康教育联合组（n=15）和利拉鲁肽组（n=15）。对健康教育联合组患者进行健康教育的同时配合利拉鲁肽单药治疗，利拉鲁肽组仅给予利拉鲁肽单药治疗，皮下注射利拉鲁肽18 mg/d，连续注射12周，对比两组的血压、体重、体重指数（BMI）、低密度脂蛋白胆固醇（LDL-C）、三酰甘油（TG）、总胆固醇（TC）、空腹 C肽（FC-P）、HOMA-IR（CP）、Homa islet（CP）、糖化血红蛋白（HbA1c）、餐后2 h血糖（2 h PG）、空腹血糖（FPG）等指标。结果治疗12周后，两组患者的FPG、2 h PG、HbA1c、体重、BMI、SB、FC-P、HOMA islet、HOMA-IR、TC、TG和LDL-C较治疗前均有明显的降低，且健康教育联合组降低更加显著，两组治疗前后差值比较，差异有统计学意义（P<0.05）。结论健康教育配合利拉鲁肽可有效作用于超重2型糖尿病患者，且效果优于单独利拉鲁肽治疗，能有效控制超重2型糖尿病患者的体重，降低血压，控制FPG及2 h PG，并能起到调脂的作用。
Abstract：ObjectiveTo explore the treatment methods of health education with Liraglutide monotherapy treatment of newly diagnosed overweight patients with type 2 diabetes,which can further provide the theoretical basis and reference for clinical application.Methods30 cases of overweight patients with type 2 diabetes from June 2014 to May 2016 in our hospital were selected as the research object,they were divided into education united group(n=15)and Liraglutide group (n=15)using the random number table method.Liraglutide group was given a separate Liraglutide monotherapy, subcutaneous injection,18 mg/d,injection 12 weeks in a row,education united group was given Liraglutide monotherapy and health education.Then the difference of blood pressure,body weight,body mass index (BMI),low density lipoprotein cholesterol(LDL-C),triglyceride(TG),total cholesterol(TC),fasting C peptide(FC-P),HOMA-IR(CP),HOMA IR islet(CP), glycosylated hemoglobin(HbA1c),postprandial 2 h blood glucose(2 h PG),fasting plasma glucose(FPG),and other indicators was compared between the two groups.ResultsThe FPG,2 h PG,HbA1c,weight,BMI,SB,FC-P,HOMA islet,HOMA-IR, TC,TG and LDL-C were significantly lower compard with before treatment,and education united group had more significantly reduce compared with Liraglutide group,the difference value of before and after treatment in the two groups had statistically significant difference(P<0.05).ConclusionThe combination with health education and Liraglutide is a kind of effective treatment to overweight type 2 diabetes patients,and superior than the Liraglutide monotherapy,because it can effectively control overweight type 2 diabetes patients with body weight,lower blood pressure,FPG,2 h PG,and it plays a role in lipid regulation as well.
王海燕;刘慧霞. 健康教育配合利拉鲁肽单药治疗新诊断超重2型糖尿病患者的临床分析[J]. 中国当代医药, 2017, 24(11): 51-54.
WANG Hai-yan;LIU Hui-xia. Clinical analysis of health education with Liraglutide monotherapy treatment of newly diagnosed overweight patients with type 2 diabetes. 中国当代医药, 2017, 24(11): 51-54.
京公网安备 11010502046607号